Mapp Biopharmaceutical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Mapp Biopharmaceutical is a private, clinical-stage biotech focused on developing monoclonal antibody countermeasures against deadly viral threats like Nipah, Marburg, and Junín viruses. The company leverages strategic partnerships, notably with BARDA, to advance its pipeline through non-clinical and clinical development. With a mission-driven approach to global health and biodefense, Mapp is progressing multiple candidates, including one now in human trials for Nipah virus, positioning it as a key player in the preparedness and response landscape for emerging infectious diseases.

Infectious DiseasesBiodefense

Technology Platform

Discovery and engineering of human/humanized monoclonal antibodies, including Fc modification (e.g., afucosylation) for enhanced efficacy against viral pathogens.

Opportunities

The increasing global focus on pandemic preparedness and biodefense is driving significant and sustained government funding for medical countermeasures.

Successful clinical advancement of its lead candidates could lead to lucrative procurement contracts for the U.S.

Strategic National Stockpile and create opportunities for partnerships with global health organizations during outbreak responses.

Risk Factors

The company is highly dependent on U.S.

government funding, making it vulnerable to shifts in political and budgetary priorities.

The development pathway under the FDA's Animal Rule is complex and risky, requiring exceptional efficacy in animal models.

The commercial market outside of government procurement is virtually non-existent, creating a single-customer dependency.

Competitive Landscape

Mapp competes in a niche segment with other biotechs, non-profits, and large pharma companies (e.g., Regeneron, Ridgeback) that also develop therapeutics for high-consequence pathogens, often with government support. Its competitive edge lies in its long-standing expertise in antibody engineering for filoviruses and henipaviruses, proven non-human primate data, and strong relationships with key government agencies like BARDA.

More companies in Small Molecule Drugs →More companies in United States →